Clinical Trial Update: A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Budesonide/Glycopyrronium/Formoterol Fumarate MDI versus placebo MDI to assess heart and lung function in chronic obstructive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) (budesonide/glycopyrronium/formoterol fumarate)
• Placebo MDI

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease, Hyperinflation | Phase 4 | Status: RECRUITING